Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global interventional cardiology devices market was valued at US$ 18.1 billion in 2022 and is expected to register a revenue CAGR of 8.1% to reach US$ 36.6 billion by 2031.

Interventional Cardiology Devices Market Fundamentals 

Interventional cardiology uses specialized catheter-based devices employed to diagnose and treat coronary artery disease, cardiovascular disease, structural heart disease, and congenital heart defects. Using various diagnostic equipment and imaging techniques, interventional cardiology devices help monitor cardiovascular functions, including blood pressure and blood flow in significant arteries across the body and within the various heart chambers. Traditional open cardiac procedures are not carried out in interventional cardiology.

Interventional cardiology procedures include cardiac catheterization, which evaluates the endurance of the heart muscle and the efficiency of the heart valves as well as the existence, size, and location of plaque deposits in the arteries. Further, percutaneous coronary intervention, generally called angioplasty, attempts to widen a coronary artery so that blood flow can be resumed. It can be a scheduled procedure to treat persistently insufficient blood supply to the heart or an emergency treatment for someone experiencing a heart attack. Depending on the patient’s specific anatomy, a cardiologist selects the best tool to repair the cardiac vessels.

Before the advancement of trans-radial cardiac catheterizations and interventions, patients would undergo catheterizations to access the artery system through the groin, resulting in various issues. Patients experience significant discomfort due to this procedure, which is still provided by medical professionals who lack the necessary certification in interventional cardiology. Increased recovery times are frequently the result of patients enduring the painful aftereffects of the treatment. Due to the treatment’s nature, patients frequently experience increased bleeding, hematomas, and pseudoaneurysms in the surgical site along the femoral artery. Frequent catheterization complications, such as retroperitoneal hemorrhaging, can potentially be deadly to some individuals. Moreover, interventional cardiology does not operate in this manner. The need for interventional cardiology devices has increased owing to the high patient-doctor preferences. 

[546456]

Interventional Cardiology Devices Market Dynamics

With an estimated 17.9 million deaths each year, cardiovascular illnesses are the leading cause of death worldwide. Cardiovascular diseases include blood vessel disease and coronary heart disease. At the age of 70, one-third of all deaths from cardiovascular disorders are caused by heart attacks and strokes, which account for more than four out of every five fatalities. The most significant behavioral risk factors for heart disease and stroke are eating inadequately, smoking, being inactive, and consuming excessive alcohol. People may have signs including obesity and excessive blood pressure from a sedentary lifestyle. As a result, cardiovascular diseases possess a high emergence globally. These variables are fueling revenue growth in the interventional cardiology devices market. According to the WHO, 60% of the factors influencing a person’s well-being and standard of living are associated with their lifestyle. Millions of people lead unhealthy lifestyles, resulting in a high prevalence of cardiovascular diseases. Diet is the most important aspect of lifestyle that directly and positively impacts health. A poor diet and its consequences, such as obesity, are common health issues in urban civilizations. Urban living causes nutrition problems, such as the consumption of fast food and unhealthy foods, which increases the risk of illnesses such as cardiovascular disease. As a result, people suffer from disease, impairment, and even death. An unhealthy lifestyle can lead to metabolic disorders, joint and bone problems, cardiovascular diseases, hypertension, obesity, violence, and other problems.

Frequent technological breakthroughs enable the creation of minimally invasive coronary stents, high precision, and improved dependability. Raising adoption rates enhances market revenue growth. Furthermore, the market for interventional cardiology devices will expand due to the high number of patients with coronary heart disorders with an increase in the demand for coronary intervention procedures. To fulfill the increasing patient demand, key companies are increasing efforts and initiatives on developing minimally invasive coronary stents, driving up demand for interventional cardiology devices. The rise in the prevalence of numerous chronic and lifestyle disorders and the growth in the patient preference for less invasive surgeries are driving the demand for the interventional cardiology devices market.

Minimally invasive surgeries are always preferred over open surgery owing to their multiple benefits. A surgeon will only need to create a small incision to reach the heart, allowing them to complete the procedure more quickly and with much less risk to the patient. Also, a shorter hospital stays with fewer complications result from the body experiencing less stress. In reality, many minimally invasive treatments are considered outpatient surgeries, requiring the patient to leave the hospital the following day. The key benefits of employing the interventional cardiology technique are avoiding incisions, suffering, and protracted postoperative recovery. Furthermore, primary angioplasty, an interventional cardiology procedure, is currently the gold standard of treatment for acute myocardial infarction.

The global market for interventional cardiology devices is expanding due to the rapidly aging population, improved patient awareness of cardiovascular illnesses, and the growing demand for patient monitoring and treatment. Numerous governmental and non-governmental organizations, educational institutions, and significant market participants have started public awareness campaigns to spread information about illnesses and their treatments and the availability of more sophisticated technologies and procedures at healthcare facilities. The development of more sophisticated and inventive cardiovascular devices and the simplicity with which regulatory licenses can be obtained are other factors driving market expansion.

The advancement of technology in the market is a key factor fueling the revenue growth of the interventional cardiology devices market. Transcatheter aortic valve replacement technology is receiving significant investment from the top interventional cardiology device corporations, who are also buying up multiple start-up businesses.

However, the development of the market is constrained by a stringent regulatory framework and a dearth of efficient first-line therapeutics.

Interventional Cardiology Devices Market Ecosystem

The global interventional cardiology devices market is analyzed from two perspectives: type and region.

Interventional Cardiology Devices Market by Type

[75464]

On the basis of type, the global interventional cardiology devices market is segmented into angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, and others.

The angioplasty stents segment accounted for the largest revenue share of the global interventional cardiology devices market in 2022. A thin wire mesh tube, a stent, is commonly inserted with an angioplasty. The stent aids in maintaining the artery open, reducing the likelihood of further narrowing. Medicine is typically coated on most stents, such as drug-eluting stents, to maintain the artery intact. The usage of bare-metal stents is rare. Chest pain and shortness of breath are examples of symptoms of blocked arteries that angioplasty can improve. Angioplasty is frequently performed to unblock a blocked artery rapidly during a heart attack and lessen the amount of cardiac damage.

Interventional Cardiology Devices Market by Region

Based on the region, the global interventional cardiology devices market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

North America accounted for the largest revenue share of the global interventional cardiology devices market in 2022. The United States accounts for a large share of the burden of cardiovascular diseases in North America due to its sizable population and evolving lifestyles. According to estimates, heart disease, which includes hypertension, strokes, and coronary heart problems, is the main cause of death in the United States. The American Heart Association estimates that by 2035, about 45% of Americans are likely to have heart disease due to high obesity, excessive smoking, and unhealthy lifestyles, which cause heart attacks and other related problems. Due to the expansion of the healthcare system in the United States, North America is the most industrialized region of the world in terms of healthcare. The need for cardiac surgeries is increasing in the United States, which is fueling the interventional cardiology devices market revenue growth. This is due to the higher acceptance of novel technologies by the American population and the increase in focus on lowering the burden of heart disease. 

Asia Pacific is likely to grow at high revenue CAGR during the forecast period. Government initiatives and the involvement of significant companies in the region are the major reasons to fuel market revenue growth. For instance, the cost of drug-eluting stents dramatically decreased in January 2021 when the Chinese Government introduced a coordinated procurement process for high-value medical supplies. To win the national tender, the average price of drug-eluting stents was reduced by 93% from 2019 prices. 

Interventional Cardiology Devices Market Competitive Landscape 

The key companies operating in the market are:

• Abbott Laboratories
• B. Braun Melsungen AG
• Boston Scientific Corporation
• Becton, Dickinson, and Company
• Cardinal Health Inc.
• Cook Group
• Medtronic plc
• Terumo Group
• Koninklijke Philips N.V.
• Biotronik SE & Co. KG
• Biosensors International Group 
• Edward Lifesciences Corporation
• iVascular

Interventional Cardiology Devices Market Strategic Developments 

• In February 2022, Cardiovascular Systems, Inc. partnered with Innova Vascular, Inc. (Innova) to develop a full line of novel thrombectomy devices
• In May 2022, Medtronic plc received United States Food and Drug Administration (FDA) approval for the Onyx Frontier drug-eluting stent (DES)
• In January 2021, Boston Scientific received FDA approval for its Synergy Megatron Drug-eluting stent system, designed for treating large proximal near the aorta 
• In February 2021, iVascular launched new lengths for the Angiolite drug-eluting stent (DES) to treat long lesions in the coronary arteries. The 44mm and 49mm lengths received the European CE Mark approval for treating diffuse lesions. 
• In March 2021, the United States FDA approved the first in the world non-surgical heart valve to treat pediatric and adult patients with a native or surgically repaired right ventricular outflow tract, the part of the heart that carries blood out of the right ventricle to the lungs. 
• In May 2021, NiTiDES, a novel polymer-free self-expanding Amphilimus eluting stent from Alvimedica for superficial femoral artery lesions, received the CE mark.
• In July 2021, ORIGIN SC and ORIGIN NC, two high-performance balloons for vessel preparation, were introduced by MedAlliance, a privately held medical technology company dedicated to developing novel drug-eluting balloons for patients suffering from life-threatening coronary and peripheral arterial disease.
• In July 2021, Abbott launched its XIENCE family of stents, which received the US FDA approval for one-month DAPT labeling for high-bleeding risk patients in the United States. In addition, XIENCE stents received the CE Mark approval for DAPT in 28 days, thus ensuring XIENCE stents have the shortest DAPT indication in the world.
• In September 2021, Biotronk SE & Co. KG received FDA approval and the First Implant of the Orsiro Mission Drug-Eluting Stent System in the U.S.
• In June 2020, Edward Lifesciences Corporation (US) received Chinese regulatory approval for the SAPIEN 3 Transcatheter Heart Valve for the treatment of patients suffering from severe, symptomatic aortic stenosis
• In October 2020, Biosensors International Group Ltd announced European CE Mark approval for the company’s new BioFreedom Ultra drug-coated coronary stent system

Frequently Asked Questions About This Report